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Background: There is still little data about long term results of unprotected left main
stenting. In a multicenter randomized trial we compared percutaneous coronary
intervention (PCI) using Sirolimus eluting stents to bypass revascularisation (CABG)
for patients with significant left main stenosis. We present the cumulative 5-years
results and therefore the longest available results of a randomized left main study at
all.
Methods: Between 8/2003 and 9/2008 a total of 201 pts with hemodynamically
significant stenosis of the unprotected left main coronary artery were recruited in 4
german centers. The primary endpoint of the study was death, myocardial infarction,
stroke and target vessel re-intervention. Hundred patients were randomized within the
PCI-group and 101 patients within the CABG-group. There were no differences in the
baseline characteristics. The left main lesion was located at the ostium in 22%, midshaft
in 8% and at the bifurcation in 70%. Nearly half of the CABG patients were operated
on using an off-pump technique (46%) and with total arterial revascularization in 65%.
Complete revascularization was achieved in both groups.
Results: Over a cumulative period of 5 years, 14 pts (14.1%) within the CABG group
and 11 pts (11.1%) within the PCI group died. Myocardial infarction occurred in 2
patients after CABG and in 4 PCI patients after PCI. One patient had a stroke in the
PCI group and 2 patients in the CABG group. The incidence of stroke was found to be
low (1 vs 2 within the PCI and CABG group, respectively). Reintervention within the
PCI group was required in 20 patients (3/20 underwent CABG) vs 9 patients within
the CABG goup. Cumulative MACCE rate after 5 years was 36.4% for the PCI group
vs 27.3% for the CABG group (p = 0.16 for non-inferiority).
Conclusion: In patients with unprotected left main stenosis, mortality during a 5-year
follow-up was found is low. There were no significant differences in the primary
endpoints death, myocardial infarction and stroke between the 2 treatments groups.
However, for overall MACCE rate, non-inferiority for PCI could not be demonstrated.
This was a result of a higher rates of target vessel re-intervention within the PCI group
during follow-up
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Background: The aim of this study was to evaluate the long-term safety and efficacy
of the titanium-nitride-oxide-coated (TITANOX) stent and the paclitaxel-eluting stent
(PES) in patients with acute myocardial infarction (MI) treated with a percutaneous
coronary intervention (PCI).
Methods: Altogether 425 patients presenting with acute non-ST-elevation MI or ST-
elevation MI were randomly assigned to receive TITANOX stent or PES during PCI.
The primary end point was a composite of MI, target lesion revascularization (TLR)
or death from cardiac causes.
Results: At 12 months, there was no significant difference between patients receiving
TITANOX stent or PES in the rate of primary end point (10.3% vs. 12.8%, p=0.5),
whereas a significantly lower rate of primary end-point was observed in the TITANOX
stent group compared with the PES group (11.2% vs. 21.8%, p<0.01) after a two-year
follow-up. After three years the rates of MI (6.1% vs. 16.6%, p<0.01), cardiac death
(1.4% vs. 5.2%, p<0.05), MACE (13.1% vs. 23.7%, p<0.01) and definite stent
thrombosis (ST) (0.5% vs. 6.6%, p<0.001) were significantly lower in the TITANOX
arm compared with the PES arm. The five-year follow-up will be completed within a
few months and the results will be presented in TCT 2011 congress if accepted.
Conclusion: The implantation of a TITANOX stent had resulted in better clinical
outcome compared with a PES during both two and three years of follow-up among
patients treated for acute MI. The long-term outcome will be updated after a five-year
follow-up.
TCT-329
Prolonged Bivalirudin Infusion is Associated with Enhanced ST Segment
Resolution Following Primary Percutaneous Coronary Intervention
Bernardo Cortese1, Ugo Limbruno2, Sara De Matteis3, Livia Diehl4, Antonino Pitì5
1Cardiologic, Cliniche Humanitas Gavazzeni, Bergamo, Italy; 2Interventional
Cardiology, Ospedale della Misericordia,, Grosseto, Italy, Italy; 3Unit of
Epidemiology, Department of Preventive Medicine, Ospedale Policlinico, Milano,
Italy, Italy; 4Cardiology, Ospedale Policlinico Milano, Milano, Italy, Italy;
5Interventional Cardiology, Ospedale Civile di Treviglio, Bergamo, Italy, Italy
Background: Bivalirudin use during primary percutaneous coronary intervention
(PCI) is nowadays a cornerstone for the management of ST elevation myocardial
infarction (STEMI). However, an increased acute stent thrombosis rate has been found
in patients treated with bivalirudin in the Horizons-AMI trial. A prolonged infusion
after PCI has already been shown to be a safe and effective tool in patients undergoing
complex urgent or elective PCI in the Probi Viri study. We examined the effects of a
prolonged drug infusion after primary PCI.
Methods: From the database of five high-volume italian centers, we compared a group
of patients treated with a 4-hour prolonged bivalirudin infusion after PCI with two
groups treated with a normal, peri-PCI infusion and heparin+abciximab for 12 hours.
Primary study endpoint was >70% ST segment resolution (STR) within 90 minutes
after PCI, secondary endpoints were partial (>50%) STR within 90 min and intra-
hospital TIMI major and minor bleedings.
Results: Study population consisted of 264 patients undergoing primary PCI, all pre-
treated with aspirin and clopidogrel (600 mg). The three study groups did not differ
significantly for baseline characteristics. Primary endpoint in prolonged bivalirudin,
normal bivalirudin and heparin+abciximab groups was achieved respectively in 69.8%,
48.8% and 69.6% of patients (p between prolonged and standard infusion = 0.048,
between prolonged infusion and abciximab =0.98). Major bleedings and other
secondary study endpoints were not significantly different between the study groups.
Conclusion: A strategy of prolonged bivalirudin infusion after primary PCI seems
equivalent to a strategy with heparin+abciximab and better than a standard infusion in
obtaining improved early microvascular reperfusion. Further studies with a bigger
population are needed to clarify if this strategy exerts clinical benefits.
TCT-330
DES versus BMS in Large Coronary Arteries during Primary PCI
Eva C Sammut, D. A Jones, K. S Rathod, A. Graham, O. Guttman, S. M Gallagher,
A. Jain, C. Knight, A. Mathur, A. Wragg
Cardiology, The London Chest Hospital, London, United Kingdom
Background: Recent data suggests patients with coronary disease in large arteries are
at increased risk of adverse events after PCI with first-generation drug-eluting stents
(DES) as compared with bare-metal stents (BMS). We sought to investigate this
observation in patients undergoing Primary PCI.
Methods: 2447 consecutive patients undergoing Primary PCI for STEMI at a London
centre between Oct 2003 and May 2010 were included. The primary end point used
was major adverse cardiac events (MACE) defined as death, myocardial infarction
(MI), stroke and target vessel revascularization (TVR).
Results: Of the 2447 patients 933 required stents between 3 and 4mm in diameter, 809
were BMS and 124 DES. The DES group had higher rates of diabetes (22% vs 13% p
= 0.01), previous MI (20% vs 12%, p = 0.02) and previous PCI (10% vs 5%, p=<0.04).
There was a higher average number of stents used in the DES group (1.7 vs 1.5, p
=0.03) and a higher average stent length in the DES group (19.12 vs 16.05, p=0.002).
There was a significant difference in MACE between the two groups in favour of DES
(12% BMS v 5% DES group [p = 0.04) at 3 years (figure 1). The rate of target-vessel
revascularization was significantly reduced among patients receiving DES with TVR
rates of 2.2% among patients receiving DES compared to 8.1% among those receiving
BMS(p = 0.03). There were no significant differences in the rate of death, myocardial
infarction, or stent thrombosis.
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